New pharmacological strategies for the treatment of atrial fibrillation

Annals of Noninvasive Electrocardiology

Volumn 14, Issue 3, 2009, Pages 290-300

  Burashnikov, Alexander ^a   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Antiarrhythmic drugs; Cardiac arrhythmias; Electrophysiology; Pharmacology

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ACACETIN; ACETYLCHOLINE; ALMOKALANT; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; AVE1231; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DPO 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; ION CHANNEL; ISQ 1; LIDOCAINE; MEXILETINE; MK499; MORACIZINE; N METHYL N [2 [METHYL(1 METHYL 1H BENZIMIDAZOL 2 YL)AMINO]ETHYL] 4 [(METHYLSULFONYL)AMINO]BENZENESULFONAMIDE; NIP141; NIP142; PRAJMALINE; PROPAFENONE; QUINIDINE; RANOLAZINE; S20951; S9947; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TEDISAMIL; UNCLASSIFIED DRUG; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; DILATATION; DISEASE MANAGEMENT; DISEASE PREDISPOSITION; DRUG EFFECT; GAP JUNCTION; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; PROPAFENONE;

EID: 67649405199     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2009.00305.x     Document Type: Review

References (97)

1. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
2. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 358 : 2667 2677.
3. Morrow JP, Cannon CP, Reiffel JA. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: What are our therapies likely to be by 2010 and beyond? Am Heart J 2007 154 : 824 829.
4. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: Current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 2008 10 : 647 665.
5. Mazzini MJ, Monahan KM. Pharmacotherapy for atrial arrhythmias: Present and future. Heart Rhythm 2008 5 : S26 S31.
6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006 48 : 854 906. (Pubitemid 44175743)
7. Viskin S, Barron HV, Heller K, et al. The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies. Curr Probl Cardiol 1997 22 : 37 108.
8. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007 356 : 935 941.
9. K,ACh is constitutively active in patients with chronic atrial fibrillation. Circulation 2005 112 : 3697 3706.
10. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006 5 : 1034 1049.
11. Blaauw Y, Gogelein H, Tieleman RG, et al. "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004 110 : 1717 1724.
12. Knobloch K, Brendel J, Rosenstein B, et al. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit 2004 10 : BR221 BR228.
13. Wirth KJ, Brendel J, Steinmeyer K, et al. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 2007 49 : 197 206.
14. Regan CP, Stump GL, Wallace AA, et al. In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol 2007 49 : 236 245.
15. Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007 50 : 35 40.
16. Goldstein RN, Khrestian C, Carlsson L, et al. Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004 15 : 1444 1450.
17. Seki A, Hagiwara N, Kasanuki H. Effects of NIP-141 on K currents in human atrial myocytes. J Cardiovasc Pharmacol 2002 39 : 29 38.
18. Matsuda T, Takeda K, Ito M, et al. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J Pharmacol Sci 2005 98 : 33 40.
19. Li GR, Wang HB, Qin GW, et al. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation 2008 117 : 2449 2457.
20. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation 2008 117 : 1518 1525.
21. Crijns HJ, Van GI, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006 3 : 1321 1331.
22. Fedida D. Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007 16 : 519 532.
23. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 2006 47 : 123 132. (Pubitemid 44378235)
24. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007 116 : 1449 1457.
25. Kur promote atrial fibrillation? Heart Rhythm 2008 5 : 1304 1309.
26. Feng J, Xu D, Wang Z, et al. Ultrarapid delayed rectifier current inactivation in human atrial myocytes: Properties and consequences. Am J Physiol 1998 275 : H1717 H1725.
27. v1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 2008 51 : 380 387.
28. Workman AJ, Kane KA, Rankin AC. Cellular bases for human atrial fibrillation. Heart Rhythm 2008 5 : S1 S6.
29. Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006 15 : 2185 2191.
30. Kur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation. Circulation 2004 110 : 2299 2306.
31. Kur block. Am J Physiol 2004 286 : H2393 H2400.
32. Kur blockers 3-[(dimethylamino)methyl]-6- methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl- 2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure. J Pharmacol Exp Ther 2008 324 : 322 330.
33. Camm AJ, Savelieva I. New antiarrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant. J Interv Card Electrophysiol 2008 23 : 7 14.
34. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: Do they exist? J Cardiovasc Pharmacol 2008 52 : 121 128.
35. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002 105 : 2753 2759.
36. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004 109 : 327 334. (Pubitemid 38133899)
37. Heidbuchel H, Callewaert G, Vereecke J, et al. Membrane-bound nucleoside diphosphate kinase activity in atrial cells of frog, guinea pig, and human. Circ Res 1992 71 : 808 820.
38. Ehrlich JR, Cha TJ, Zhang L, et al. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 2004 557 : 583 597.
39. K,ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res 2007 74 : 426 437.
40. Cha TJ, Ehrlich JR, Chartier D, et al. Kir3-based inward rectifier potassium current: Potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006 113 : 1730 1737.
41. K,ACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res 2006 54 : 136 141.
42. Ravens U. Potassium channels in atrial fibrillation: Targets for atrial and pathology-specific therapy? Heart Rhythm 2008 5 : 758 759.
43. Ehrlich JR, Biliczki P, Hohnloser SH, et al. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008 51 : 787 792.
44. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006 354 : 2677 2688.
45. Burashnikov A, Antzelevitch C. How do atrial-selective drugs differ from antiarrhythmic drugs currently used in the treatment of atrial fibrillation? J Atrial Fibrillation 2008 1 : 98 107.
46. Spinelli W, Parsons RW, Colatsky TJ. Effects of WAY-123,398, a new Class-III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs - a comparison with UK-68798, e-4031, and DL- Sotalol. J Cardiovasc Pharmacol 1992 20 : 913 922.
47. Wiesfeld AC, De Langen CD, Crijns HJ, et al. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. J Cardiovasc Pharmacol 1996 27 : 594 600.
48. Baskin EP, Lynch JJ., Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998 285 : 135 142.
49. Stump GL, Wallace AA, Regan CP, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 2005 315 : 1362 1367.
50. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994 90 : 2032 2040.
51. Echt DS, Berte LE, Clusin WT, et al. Prolongation of the human monophasic action potential by sotalol. Am J Cardiol 1982 50 : 1082 1086.
52. Buchanan LV, LeMay RJ, Walters RR, et al. Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 1996 7 : 113 119.
53. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci 2008 1123 : 105 112.
54. Burashnikov A, Belardinelli L, Antzelevitch C. Ranolazine and propafenone both suppress atrial fibrillation but ranolazine unlike propafenone does it without prominent effects on ventricular myocardium. Heart Rhythm 2007 4 : S163 (abstract).
55. Marrouche NF, Reddy RK, Wittkowsky AK, et al. High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: A prospective, randomized, double-blind crossover trial. Am Heart J 2000 139 : E8 11.
56. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999 10 : 1124 1152.
57. Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol 2006 29 : 290 295.
58. Johnson JN, Tester DJ, Perry J, et al. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008 5 : 704 709.
59. Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol 2002 34 : 1185 1194.
60. Whalley DW, Wendt DJ, Grant AO. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs. Pacing Clin Electrophysiol 1995 18 : 1686 1704.
61. Langenfeld H, Weirich J, Kohler C, et al. Comparative analysis of the action of class I antiarrhythmic drugs (lidocaine, quinidine, and prajmaline) in rabbit atrial and ventricular myocardium. J Cardiovasc Pharmacol 1990 15 : 338 345.
62. Furukawa T, Koumi S, Sakakibara Y, et al. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. J Mol Cell Cardiol 1995 27 : 831 846.
63. Ahmmed GU, Hisatome I, Kurata Y, et al. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes. Atrioventricular difference of moricizine block. Vascul Pharmacol 2002 38 : 131 141.
64. Nemeth M, Virag L, Hala O, et al. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc Res 1996 31 : 246 248.
65. max) of action potential in guinea-pig cardiac muscles. J Mol Cell Cardiol 1987 19 : 367 377.
66. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007 116 : 1647 1652.
67. Antzelevitch C. Ranolazine: A new antiarrhythmic agent for patients with non-ST-segment elevation acute coronary syndromes? Nat Clin Pract Cardiovasc Med 2008 5 : 248 249.
68. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Therapeut 2004 9 (Suppl 1 S65 S83.
69. Billman GE, Kukielka M. Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia. J Cardiovasc Pharmacol 2008 51 : 352 358.
70. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol 1996 491 (Pt 1 31 50.
71. Nattel S, Matthews C, De Blasio E, et al. Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : Potential relevance to ionic mechanisms in vivo. Circulation 2000 101 : 1179 1184.
72. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med 2007 4 : 110 116.
73. Christe G, Tebbakh H, Simurdova M, et al. Propafenone blocks ATP-sensitive K+ channels in rabbit atrial and ventricular cardiomyocytes. Eur J Pharmacol 1999 373 : 223 232.
74. Goette A, Bukowska A, Lendeckel U. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr Opin Pharmacol 2007 7 : 219 224.
75. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008 5 : 30 41.
76. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006 152 : 86 92.
77. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007 154 : 448 453.
78. Berkowitsch A, Neumann T, Kuniss M, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and atrial fibrillation after pulmonary vein isolation. Heart Rhythm 2008 5 : S265 (abstract).
79. Jang JK, Park JS, Kim YH, et al. Effects of the therapy with statins, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blocker on the outcome after catheter ablation of atrial fibrillation. Heart Rhythm 2008 5 : S324 (abstract).
80. 1 transgene in the heart. Circ Res 2000 86 : 571 579.
81. Dudley SC, Jr., Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation 2005 112 : 1266 1273.
82. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ Arrhythmia Electrophysiol 2008 1 : 62 73.
83. Burstein B, Libby E, Calderone A, et al. Differential behaviors of atrial versus ventricular fibroblasts: A potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008 117 : 1630 1641.
84. Shimano M, Tsuji Y, Inden Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008 5 : 451 459.
85. Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: Implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008 117 : 344 355.
86. Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 2008 65 : 1489 1508.
87. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004 63 : 236 244.
88. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004 165 : 1019 1032.
89. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004 94 : 1458 1465.
90. Adam O, Frost G, Custodis F, et al. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007 50 : 359 367.
91. Burashnikov A. Are there atrial selective/predominant targets for "upstream" atrial fibrillation therapy? Heart Rhythm 2008 5 : 1294 1295.
92. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 : 987 999.
93. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008 358 : 2678 2687.
94. Xing D, Kjolbye AL, Nielsen MS, et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 2003 14 : 510 520.
95. Eloff BC, Gilat E, Wan X, et al. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: Evidence supporting a novel target for antiarrhythmic therapy. Circulation 2003 108 : 3157 3163.
96. Guerra JM, Everett TH, Lee KW, et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006 114 : 110 118.
97. Shiroshita-Takeshita A, Sakabe M, Haugan K, et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007 115 : 310 318.